Reuters logo
BRIEF-UCB posts full-year recurring EBITDA of 689 mln euros
February 26, 2014 / 6:16 AM / 4 years ago

BRIEF-UCB posts full-year recurring EBITDA of 689 mln euros

BRUSSELS, Feb 26 (Reuters) - U C B SA : * FY revenue of EUR 3,411 million * FY underlying profitability (recurring EBITDA) up to EUR 689 million * Gross dividend of EUR 1.04 per share (+2%) proposed by board of directors * Revenue 2014 to grow to approx. EUR 3.5-3.6 billion * 2014 recurring EBITDA to increase to approx. EUR 740-770 million. core EPS

expected in the range of EUR 1.90 - 2.05. * Keppra FY net sales of 712 million * Cimzia for inflammatory arthritis indications and crohn’s disease increased

FY net sales by 27% to EUR 594 million * FY net sales of the anti-epileptic medicine vimpat increased to EUR 411

million * Neupro, the patch for parkinson’s disease and restless legs syndrome

increased FY net sales to EUR 182 million

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below